Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of AMG 570 (Rozibafusp alfa)
NCT02618967Phase 1Completed
- Sponsor
- Amgen
- Start
- Mar 2016
- Primary completion
- Sep 2018
- Modality
- Bispecific Antibodies, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rozibafusp alfa in systemic lupus erythematosus (SLE) (8 arms), sponsored by Amgen. Primary endpoints: Number of Participants Who Experienced One or More Treatment-emergent Adverse Events, Number of Participants Who Experienced a Clinically Significant Change in Physical Examinations and 3 more. Started Mar 2016; status: completed.
02
Drugs
rozibafusp alfa
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02618967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02618967.